Gadolinium-based MR cisternography with prepontine cisternal routine for evaluating distribution pattern of intrathecal targeted drug delivery in pain management

Drug Deliv. 2023 Dec;30(1):2189588. doi: 10.1080/10717544.2023.2189588.

Abstract

Gadolinium-based MR cisternography has been mainly applied in clinical evaluation of cerebrospinal fluid leaking, that is conducted by intrathecal administration of contrast media. Recently, we have reported one novel technique of intrathecal targeted drug delivery with prepontine cisternal routine to treat orofacial cancer pain. The aim of this study was to examine the distribution pattern of this intrathecal drug delivery strategy. Here, we introduce one case who suffered severe orofacial pain caused by sublingual gland tumor, and successfully attenuated by prepontine cisternal administration of analgesic agents. To assess the distribution of intrathecal drugs, postoperative MR images of brain, cervical, thoracic, and lumbar segments in axial, coronal, and sagittal planes were obtained after application of gadolinium. The perfusion rate of contrast medium was set at 0.01 mmol per hour for 24 hours prior to MR scanning. In the T1-weighted images, we can identify contrast spread not only locating around the site of the intrathecal catheter tip, but also concentrated to the lateral sides. None obvious side effect was found after intrathecal injection of contrast media. Thus, our finding demonstrated the local distribution phenomenon of intrathecal drugs through prepontine cisternal access, and the bilateral perfusion pattern may provide insights underlying the analgesic mechanism of trigeminal pain provided by this novel intrathecal therapy. Gadolinium-based MR cisternography may serve as a potential tool to confirm the therapeutic effect of intrathecal targeted drug delivery via prepontine cisternal routine in orofacial pain management.

Keywords: Gadolinium; cisternography; distribution; intrathecal targeted drug delivery; prepontine cisternal.

MeSH terms

  • Contrast Media*
  • Gadolinium DTPA
  • Gadolinium*
  • Humans
  • Magnetic Resonance Imaging / methods
  • Pain / drug therapy
  • Pain Management

Substances

  • Contrast Media
  • Gadolinium
  • Gadolinium DTPA

Grants and funding

This research was funded by Natural Science Foundation of Hunan Province (2020JJ4811), Key Research and Development Program of Hunan Province (2020SK2079), Key Laboratory of Hunan Province grants (2018TP1009), and Huizhiyucai Project of the Third Xiangya Hospital, Central South University.